Journal
JOURNAL OF CLINICAL PSYCHIATRY
Volume 71, Issue 8, Pages 1047-1054Publisher
PHYSICIANS POSTGRADUATE PRESS
DOI: 10.4088/JCP.09m05650blu
Keywords
-
Categories
Funding
- AstraZeneca
- Bristol-Myers Squibb
- Eisai
- Eli Lilly
- GlaxoSmithKline
- Janssen-Cilag
- Lundbeck
- Merck
- Novartis
- Organon
- Pfizer
- Sanofi-Aventis
- Schwabe
- Sepracor
- Servier
- Wyeth
- Bayer
- Boehringer Ingelheim
- Merz
- Steigerwald
- Teva
- German Federal Ministry of Education and Research
- Lundbeck GmbH
- Servier Deutschland GmbH
- Lilly
- Pharmacia
- esparma
Ask authors/readers for more resources
Objective: The objective of this study was to explore the prevalence of anxious depression in an inpatient population, to describe its clinical and sociodemographic correlates, and to compare treatment outcomes between patients with anxious and nonanxious depression. Furthermore, the efficacy of algorithm-guided treatment versus treatment as usual in patients with anxious versus nonanxious depression was evaluated. Method: Data were collected on 429 inpatients with the diagnosis of a depressive episode (according to ICD-10) and a score of >= 15 on the 21-item Hamilton Depression Rating Scale (HDRS-21). The German Algorithm Project, phase 3 (GAP3), was conducted between 2000 and 2005 in 10 psychiatric departments throughout Germany. A baseline HDRS-21 anxiety/somatization factor score of 7 was considered indicative of anxious depression. Remission was defined as an HDRS-21 score <= 9. To evaluate the efficacy of algorithm-guided treatment, patients were randomly assigned into 3 groups: 2 different treatment algorithms or treatment as usual. Results: The prevalence of anxious depression was 49%. Patients with anxious depression were more likely than those with nonanxious depression to be older (mean +/- SD = 45.3 +/- 12.8 vs 42.9 +/- 12.0 years, odds ratio [OR]=1.02 [95% CI, 1.00-1.03], P=.046), retired (70% vs 30%, OR=3.09 [95% CI, 1.70-5.62], P=.000), without school qualification (74% vs 26%, OR=3.11 [95% CI, 1.09-8.83], P=.035), more severely depressed (mean +/- SD HDRS-21 score = 20.1 +/- 5.0 vs 18.5 +/- 4.4, OR = 1.08 [95% CI, 1.03-1.12], P=.001), and more likely to have a longer duration of the current episode (mean +/- SD=20.9 +/- 26.2 vs 13.7 +/- 14.3 weeks, OR=1.02 [95% CI, 1.01-1.03], P=.011). Patients with anxious depression were more likely to display a variety of melancholic features. In patients with anxious depression compared to those with nonanxious depression, remission was less likely to be achieved (48.6% vs 61.5%, OR = 0.63 [95% CI, 0.42-0.92], P=.018) and took longer to occur (mean +/- SD = 44 +/- 3.4 vs 30 +/- 2.8 days, HR=0.65 [95% CI, 0.50-0.85], P=.001). There was no significant interaction with the treatment mode with regard to remission (Wald=0.20, P=.890). Conclusions: Anxious depression is common in patients diagnosed with depression. The poorer treatment outcome in patients with anxious depression demonstrates the need to address the issue of specific treatment strategies for this subgroup. However, anxious depression has no moderating effect on the efficacy of algorithm-guided treatment. Trial Registration: http://www.germanctr.de/ Identifier: DRKS00000161 J Clin Psychiatry 2010;71(8):1047-1054 (C) Copyright 2010 Physicians Postgraduate Press, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available